HomeNDC LookupIngredientsCiclopirox › 45802-0401-09
Ciclopirox 1 g/100mL Shampoo, 120 mL — NDC 45802-0401-09 package photo

Ciclopirox 1 g/100mL Shampoo, 120 mL

by Padagis Israel Pharmaceuticals Ltd · 120 mL in 1 BOTTLE (45802-401-09)
NDC 45802-0401-09
🏷️ FDA NDC (as labeled) 45802-401-09 billing pads the product segment with a zero
Rx only Generic On market Non-controlled
🗂️ Data synced Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

🆔 Identity & classification

FDA NDC (as labeled) 45802-401-09
Product NDC 45802-401
11-digit billing NDC 45802040109
NCPDP billing unit ML — per mL (volume)
RxCUI 250344
UNII 19W019ZDRJ
Application # ANDA078594
SPL Set ID c3722d52-407c-499b-a08b-b299609f203c
Mechanism of action Protein Synthesis Inhibitors
Physiologic effect Decreased DNA Replication; Decreased Protein Synthesis; Decreased RNA Replication
DEA schedule Non-controlled
Marketing category ANDA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2010-02-17
Route TOPICAL
Dosage form SHAMPOO
Substance CICLOPIROX
GPI-14 90150030004510
GPI class Ciclopirox
GCN Seq No 051825
GCN 19218
HICL code 016915
Ingredient (HICL) Ciclopirox
HIC1 code Q
Therapeutic class — broad (HIC1) Ear/Eye/Nose/Rectum/Topical/Vagina/Other
HIC2 code Q5
Therapeutic class — intermediate (HIC2) Agents Acting Principally On The Skin
HIC3 code Q5F
Therapeutic class — specific (HIC3) Topical Antifungals
AHFS code 84:04.08.20
AHFS class Hydroxypyridones (Skin, Mucous Membrane)
FDB label name CICLOPIROX 1% SHAMPOO
FDB brand name Ciclopirox
Legend status F — Federal legend — prescription drug or device
TE code (Orange Book) AT · RLD · RS
Why two NDCs? The FDA registers this code as 45802-401-09 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 45802-0401-09. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

🏷️ RxNorm drug class

This medicine belongs to the Other antifungals for topical use class.

Drug family (ATC) Other antifungals for topical use, Other antiinfectives and antiseptics
How it works Protein Synthesis Inhibitors
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

🏭 Manufacturer & labeler

LabelerPadagis Israel Pharmaceuticals Ltd
Application holderPADAGIS US LLC
FDA applicationANDA078594 (ANDA)
Labeler code45802
First marketedFeb 2010
Product typeHuman Prescription Drug
Portfolio175 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

🩺 Clinical

Label name CICLOPIROX 1% SHAMPOO Ingredient Ciclopirox
📗 Our plain-language guide HelloPharmacist
  • Fungal nail infections are slow to clear, and Ciclodan nail lacquer is no exception. In clinical studies, treatment lasted up to 48 weeks. Only a small percentage of patients achie...
  • How long does it take for the nail lacquer to work?
  • No — that's actually one of the most important things to get right. You apply Ciclodan once a day and leave it on. Each new coat goes right on top of the previous one. After seven...
  • Do I need to remove the nail lacquer every night before I apply a new coat?
📖 Read our full Ciclopirox Topical guide →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

🧪 Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • UNII D6DH1DTN7E
    Disodium laureth sulfosuccinate is a synthetic surfactant and emulsifier derived from lauryl alcohol. It helps mix oil and water-based ingredients together and is commonly used in topical formulations to improve product texture and spreadability.
  • UNII D4D38LT1L5
    A synthetic ingredient made from lauryl alcohol and ethylene oxide. It works as an emulsifier and surfactant to help mix water and oil-based ingredients together in the medicine.
  • UNII 451W47IQ8X
    Sodium chloride is common table salt. It's used in medicines as a buffer to maintain proper pH, as a filler to add bulk, or to adjust the osmotic balance in liquid formulations.
  • UNII BPV390UAP0
    Sodium laureth sulfate is a mild detergent and surfactant derived from coconut oil or petroleum. It helps mix oil and water in formulations and is often used as a cleaning or foaming agent in topical products like shampoos and cleansers.
  • UNII 059QF0KO0R
    Water is a liquid solvent that dissolves and mixes ingredients together in liquid medicines, syrups, and injections. It helps distribute the active drug evenly throughout the product.

5 inactive ingredients listed in the exact product block matched to this NDC.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMedingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

💲 Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer mLPer package
Retail pharmacies payNADAC · weekly $0.228 $27.31 / 120 ml
Medicaid paysCMS SDUD · 12 mo $0.3089 $37.07 / 120 ml
Medicare drug plans payPart D · Q2 2026 $0.3424 $41.09 / 120 ml
NADAC price history (per mL) — tap or hover for the price & month
Dec 2021 Jul 2022 Dec 2025 Aug 2026 $0.323 $0.225
▼ Down 20% over the last 24 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

🔁 Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Ciclopirox 10 mg/.96mL 00591-2159-90 Actavis 120 ml $0.228 AT Availability likely
Ciclopirox 1 g/100mL 21922-0105-52 Encube 1 bottle $0.228 AT Availability likely
Ciclopirox 1 g/100mLthis 45802-0401-09 Padagis 120 ml $0.228 AT Availability likely
Ciclopirox 10 mg/.96mL 51672-1351-08 Sun 1 bottle $0.228 AT Availability likely
About this product: this is a generic version of the medicine. FDA equivalence ratings are shown when available, and other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2010
On the market since
Feb 2010
📍
2026
Currently FDA-listed
16 years listed
🔓
·
Generic on the market
this product is a generic
This is a generic drug

This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

🗺️ Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for 45802-0401-09, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q4 2025 · 4 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
24.2K
Units reimbursed last 4 qtrs
3M
Gross reimbursed last 4 qtrs
$911.7K
Avg / prescription
$37.64
Avg / unit
$0.3089
Latest quarter Q4 2025
7.6KRx
Medicaid pays / mL
$0.3089
gross reimbursed
vs
NADAC / mL
$0.2276
acquisition cost
=
Spread
+$0.0813
+36% vs cost
What Medicaid paid per mL (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care
65% FFS 35% MCO
Fee-for-service · 15,688 Rx Managed care · 8,535 Rx
State Medicaid map
Alaska: no data reported AK Maine: no data reported ME Washington: 53,760 units · 688 per 100k residents WA Idaho: 4,440 units · 226 per 100k residents ID Montana: no data reported MT North Dakota: no data reported ND Minnesota: 1,320 units · 23.0 per 100k residents MN Wisconsin: 11,760 units · 199 per 100k residents WI Michigan: 38,880 units · 387 per 100k residents MI New York: 1,439,167 units · 7,354 per 100k residents NY Vermont: no data reported VT New Hampshire: 5,520 units · 394 per 100k residents NH Oregon: no data reported OR Nevada: 22,200 units · 695 per 100k residents NV Wyoming: no data reported WY South Dakota: no data reported SD Iowa: 3,120 units · 97.3 per 100k residents IA Illinois: 15,720 units · 125 per 100k residents IL Indiana: 21,840 units · 318 per 100k residents IN Ohio: 317,038 units · 2,690 per 100k residents OH Pennsylvania: 56,910 units · 439 per 100k residents PA New Jersey: 60,120 units · 647 per 100k residents NJ Massachusetts: 14,280 units · 204 per 100k residents MA California: 352,380 units · 904 per 100k residents CA Utah: 4,440 units · 130 per 100k residents UT Colorado: 16,800 units · 286 per 100k residents CO Nebraska: no data reported NE Missouri: no data reported MO Kentucky: 6,720 units · 148 per 100k residents KY West Virginia: no data reported WV Virginia: 70,200 units · 805 per 100k residents VA Maryland: 143,398 units · 2,320 per 100k residents MD Connecticut: 11,520 units · 318 per 100k residents CT Rhode Island: 7,200 units · 658 per 100k residents RI Arizona: 3,480 units · 46.8 per 100k residents AZ New Mexico: no data reported NM Kansas: 9,840 units · 335 per 100k residents KS Arkansas: no data reported AR Tennessee: 3,240 units · 45.5 per 100k residents TN North Carolina: 22,440 units · 207 per 100k residents NC South Carolina: no data reported SC Delaware: 1,440 units · 140 per 100k residents DE Oklahoma: 1,320 units · 32.6 per 100k residents OK Louisiana: 17,520 units · 383 per 100k residents LA Mississippi: no data reported MS Alabama: 26,640 units · 522 per 100k residents AL Georgia: 13,440 units · 122 per 100k residents GA D.C.: no data reported DC Hawaii: 26,160 units · 1,823 per 100k residents HI Texas: 93,480 units · 306 per 100k residents TX Florida: 53,992 units · 239 per 100k residents FL
Units reimbursed · per 100k residents
23.07,354
gray = no data reported
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 New York 7,354 /100k
2 Ohio 2,690 /100k
3 Maryland 2,320 /100k
4 Hawaii 1,823 /100k
5 California 904 /100k
6 Virginia 805 /100k
7 Nevada 695 /100k
8 Washington 688 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

📊 Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Ciclopirox — the program that covers self-administered drugs. 9 manufacturers.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Ciclopirox. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$6.35M
Claims incl. refills
257.1K
Beneficiaries
197.4K
Spend / beneficiary
$32.18
Spend / claim
$24.71
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.

🔬 Reported adverse events (FAERS)

Read carefully: FAERS reports are voluntary and unverified. Counts are not incidence, do not establish causation, are subject to reporting bias, and cannot be used to compare one drug to another. Shown for signal context only. Reports for Ciclopirox — the ingredient across all brands.

Top reported reactions

Fatigue181
Pain170
Diarrhoea147
Pruritus135
Rash135
Headache133
Dyspnoea115

Age at onset

Neonate1
Child3
Adolescent4
Adult390
Elderly286

Reporter sex

2,937 reports
Male · 45%
Female · 55%
Unknown · 0%

Serious outcomes

Hospitalization763
Death110
Life-threatening71
Disabling62
Reports over time (by year) — tap or hover for the count & year
2024 2025 2026 318 160
Most recent year is provisional (FAERS lags ~3 months).
Where does this data come from?
Adverse-event reports from the FDA Adverse Event Reporting System (FAERS) via openFDA. FAERS reports are voluntary and unverified — counts are not incidence and don’t establish causation.

📦 Packaging — all sizes for this product

Package NDCDescription Marketing startStatus
45802-0401-09 You're viewing this 120 mL in 1 BOTTLE (45802-401-09) 2010-02-17 Active

📄 Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage 44 words

1 INDICATIONS AND USAGE Ciclopirox Shampoo, 1% is indicated for the topical treatment of seborrheic dermatitis of the scalp in adults. • Ciclopirox Shampoo, 1% is an antifungal indicated for the topical treatment of seborrheic dermatitis of the scalp in adults. ( 1 )

⏱️ Dosage and Administration 142 words

2 DOSAGE AND ADMINISTRATION Ciclopirox Shampoo, 1% is not for ophthalmic, oral, or intravaginal use. Wet hair and apply approximately 1 teaspoon (5 mL) of Ciclopirox Shampoo, 1% to the scalp. Up to 2 teaspoons (10 mL) may be used for long hair.

Lather and leave on hair and scalp for 3 minutes. A timer may be used. Avoid contact with eyes.

Rinse off. Treatment should be repeated twice per week for 4 weeks, with a minimum of 3 days between applications. If a patient with seborrheic dermatitis shows no clinical improvement after 4 weeks of treatment with Ciclopirox Shampoo, 1%, the diagnosis should be reviewed. • Apply approximately 1 teaspoon of Ciclopirox Shampoo, 1% to the scalp twice per week for 4 weeks.

( 2 ) • For topical use only. Not for ophthalmic, oral, or intravaginal use. ( 2 )

💊 Dosage Forms and Strengths 41 words

3 DOSAGE FORMS AND STRENGTHS Ciclopirox Shampoo, 1% is a shampoo containing 1% ciclopirox. Each gram (equivalent to 0.96 mL) of Ciclopirox Shampoo, 1% contains 10 mg ciclopirox in a colorless and translucent shampoo base. • Shampoo, 1% ( 3 )

Contraindications 7 words

4 CONTRAINDICATIONS None. None ( 4 )

⚠️ Warnings and Cautions 92 words

5 WARNINGS AND PRECAUTIONS • If signs of irritation occur, discontinue use. ( 5.1 ) • Avoid contact with eyes. ( 5.1 ) • Hair discoloration has been reported with Ciclopirox Shampoo, 1% use. ( 5.1 )

5.1Local Effects If a reaction suggesting sensitivity or irritation occurs with the use of Ciclopirox Shampoo, 1%, treatment should be discontinued and appropriate therapy instituted. Contact of Ciclopirox Shampoo, 1% with the eyes should be avoided. If contact occurs, rinse thoroughly with water. In patients with lighter hair color, hair discoloration has been reported.

🤒 Adverse Reactions 181 words

6 ADVERSE REACTIONS • The most frequently reported adverse reactions are pruritus, burning, and erythema. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Padagis at 1-866-634-9120 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

6.1Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. In 626 subjects treated with ciclopirox shampoo, 1% twice weekly in the two pivotal clinical trials, the most frequent adverse events were increased itching in 1% of subjects, and application site reactions, such as burning, erythema, and itching, also in 1% of subjects.

6.2Post Marketing Experience The following adverse reactions have been identified during post approval use of Ciclopirox Shampoo, 1%: hair discoloration and abnormal hair texture, alopecia, irritation and rash. Because these events are reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

👥 Use in Specific Populations ~2 min read

8 USE IN SPECIFIC POPULATIONS

8.1Pregnancy Teratogenic Effects: Pregnancy Category B There are no adequate or well-controlled studies in pregnant women. Therefore, Ciclopirox Shampoo, 1% should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Oral embryofetal developmental studies were conducted in mice, rats, rabbits and monkeys.

Ciclopirox or ciclopirox olamine was orally administered during the period of organogenesis. No maternal toxicity, embryotoxicity or teratogenicity were noted at the highest doses of 77, 125, 80 and 38.5 mg/kg/day ciclopirox in mice, rats, rabbits and monkeys, respectively (approximately 13, 42, 54 and 26 times the maximum recommended human dose based on body surface area comparisons, respectively). Dermal embryofetal developmental studies were conducted in rats and rabbits with ciclopirox olamine dissolved in PEG 400.

Ciclopirox olamine was topically administered during the period of organogenesis. No maternal toxicity, embryotoxicity or teratogenicity were noted at the highest doses of 92 mg/kg/day and 77 mg/kg/day ciclopirox in rats and rabbits, respectively (approximately 31 and 54 times the maximum recommended human dose based on body surface area comparisons, respectively).

8.3Nursing Mothers It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Ciclopirox Shampoo, 1% is administered to a nursing woman.

8.4Pediatric Use No clinical trials have been conducted in subjects younger than 16 years.

8.5Geriatric Use In clinical trials, the safety and tolerability of ciclopirox shampoo, 1% in the population 65 years and older was comparable to that of younger subjects. Results of the efficacy analysis in those subjects 65 years and older showed effectiveness in 25 of 85 (29%) subjects treated with ciclopirox shampoo, 1%, and in 15 of 61 (25%) subjects treated with the vehicle; due to the small sample size, a statistically significant difference was not demonstrated. Other reported clinical experience has not identified differences in responses between the elderly and younger subjects, but greater sensitivity to adverse effects in some older individuals cannot be ruled out.

🤰 Pregnancy 176 words

8.1Pregnancy Teratogenic Effects: Pregnancy Category B There are no adequate or well-controlled studies in pregnant women. Therefore, Ciclopirox Shampoo, 1% should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Oral embryofetal developmental studies were conducted in mice, rats, rabbits and monkeys.

Ciclopirox or ciclopirox olamine was orally administered during the period of organogenesis. No maternal toxicity, embryotoxicity or teratogenicity were noted at the highest doses of 77, 125, 80 and 38.5 mg/kg/day ciclopirox in mice, rats, rabbits and monkeys, respectively (approximately 13, 42, 54 and 26 times the maximum recommended human dose based on body surface area comparisons, respectively). Dermal embryofetal developmental studies were conducted in rats and rabbits with ciclopirox olamine dissolved in PEG 400.

Ciclopirox olamine was topically administered during the period of organogenesis. No maternal toxicity, embryotoxicity or teratogenicity were noted at the highest doses of 92 mg/kg/day and 77 mg/kg/day ciclopirox in rats and rabbits, respectively (approximately 31 and 54 times the maximum recommended human dose based on body surface area comparisons, respectively).

🧒 Pediatric Use 15 words

8.4Pediatric Use No clinical trials have been conducted in subjects younger than 16 years.

🧓 Geriatric Use 107 words

8.5Geriatric Use In clinical trials, the safety and tolerability of ciclopirox shampoo, 1% in the population 65 years and older was comparable to that of younger subjects. Results of the efficacy analysis in those subjects 65 years and older showed effectiveness in 25 of 85 (29%) subjects treated with ciclopirox shampoo, 1%, and in 15 of 61 (25%) subjects treated with the vehicle; due to the small sample size, a statistically significant difference was not demonstrated. Other reported clinical experience has not identified differences in responses between the elderly and younger subjects, but greater sensitivity to adverse effects in some older individuals cannot be ruled out.

🧬 Clinical Pharmacology 185 words

12 CLINICAL PHARMACOLOGY

12.1Mechanism of Action Ciclopirox is a hydroxypyridone antifungal agent although the relevance of this property for the indication of seborrheic dermatitis is not known. Ciclopirox acts by chelation of polyvalent cations (Fe 3+ or Al 3+ ), resulting in the inhibition of the metal-dependent enzymes that are responsible for the degradation of peroxides within the fungal cell.

12.2Pharmacodynamics The pharmacodynamics of Ciclopirox Shampoo, 1% are unknown.

12.3Pharmacokinetics In a study in patients with seborrheic dermatitis of the scalp, application of 5 mL ciclopirox shampoo 1% twice weekly for 4 weeks, with an exposure time of 3 minutes per application, resulted in detectable serum concentrations of ciclopirox in 6 out of 18 patients. The serum concentrations measured throughout the dosing interval on Days 1 and 29 ranged from 10.3 ng/mL to 13.2 ng/mL. Total urinary excretion of ciclopirox was less than 0.5% of the administered dose.

12.4Microbiology Ciclopirox is fungicidal in vitro against Malassezia furfur (Pityrosporum spp.), P. ovale , and P. orbiculare . The clinical significance of antifungal activity in the treatment of seborrheic dermatitis is not known.

🧬 Mechanism of Action 58 words

12.1Mechanism of Action Ciclopirox is a hydroxypyridone antifungal agent although the relevance of this property for the indication of seborrheic dermatitis is not known. Ciclopirox acts by chelation of polyvalent cations (Fe 3+ or Al 3+ ), resulting in the inhibition of the metal-dependent enzymes that are responsible for the degradation of peroxides within the fungal cell.

📦 How Supplied / Storage and Handling 45 words

16 HOW SUPPLIED/STORAGE AND HANDLING Ciclopirox Shampoo, 1% is colorless and translucent, and supplied in 120 mL plastic bottles (NDC 45802- 401 -09). Discard unused product after initial treatment duration. Store at 20-25°C (68-77°F) [see USP Controlled Room Temperature]. Keep out of reach of children.

📋 Description 92 words

11 DESCRIPTION Ciclopirox Shampoo, 1% contains the synthetic antifungal agent, ciclopirox for topical use. Each gram (equivalent to 0.96 mL) of Ciclopirox Shampoo, 1% contains 10 mg ciclopirox in a shampoo base consisting of disodium laureth sulfosuccinate, laureth-2, purified water, sodium chloride, and sodium laureth sulfate. Ciclopirox Shampoo, 1% is a colorless, translucent solution.

The chemical name for ciclopirox is 6-cyclohexyl-1-hydroxy-4-methyl-2(1 H )-pyridone, with the empirical formula C 12 H 17 NO 2 and a molecular weight of 207.27. The CAS Registry Number is [29342-05-0]. The chemical structure is: chemical structure image

💬 Information for Patients 103 words

17 PATIENT COUNSELING INFORMATION See FDA-approved patient labeling (Patient Information). The patient should be instructed to: • Use Ciclopirox Shampoo, 1% as directed by the physician. Avoid contact with the eyes.

If contact occurs, rinse thoroughly with water. Ciclopirox Shampoo, 1% is for external use on the scalp only. Do not swallow. • Use Ciclopirox Shampoo, 1% for seborrheic dermatitis for the full treatment time even though symptoms may have improved.

Notify the physician if there is no improvement after 4 weeks. • Inform the physician if the area of application shows signs of increased irritation (redness, itching, burning, blistering, swelling, or oozing).

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.